Posts tagged prostate-specific antigen test
Prostate cancer study shows benefit of 3DS’ telomere signature analysis

Data from a new study published recently in Urologic Oncology involving men with localized high-risk prostate cancer suggests that the use of 3D Signatures’ (OTCQB:TDSGF; TSX-V:DXD) technology platform, TeloView, may be a promising blood-based treatment-response biomarker in prostate cancer patients who are undergoing combined androgen deprivation therapy (ADT) and radiation therapy (RT).

Read More